Our in vitro and in vivo experiments have demonstrated that FOS suppresses B-ALL leukemogenesis and serves as a bona fide tumor-suppressor downstream target of ZNF217 in B-ALL. The gene discussed is FOS; the disease is precursor B-cell acute lymphoblastic leukemia.